Lacedor (Morphine Hydrochloride Trihydrate)

Morphine Hydrochloride binds to mu‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that reduce neuronal excitability. This action decreases the release of neurotransmitters involved in pain signaling, leading to diminished perception of pain and increased analgesic effect.

The appropriate dose of Lacedor is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, route of administration, and clinical condition. Dosage adjustments may be required for renal or hepatic impairment, age, or concomitant medications.

Safety data for Morphine Hydrochloride in pregnancy and lactation are limited. It is generally classified as contraindicated or used only when the potential benefit justifies the risk to the fetus or infant. Clinicians should evaluate risks carefully and consider alternative therapies when possible.

To order Lacedor, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lacedor (morphine) and fentanyl are both potent opioids but differ in pharmacokinetics and potency. Morphine has a longer onset and duration, making it suitable for continuous infusion via epidural or intrathecal routes, whereas fentanyl is more lipophilic, acts faster, and is often used for short‑acting analgesia. Choice depends on clinical context, required duration, and patient response.

Lacedor should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Lacedor is administered by a qualified healthcare professional via epidural, intramuscular, or intrathecal injection. The specific route is selected based on the clinical indication, required speed of analgesia, and patient factors. Proper aseptic technique and dosing guidelines must be followed for each administration method.

The most serious risks include respiratory depression, severe hypotension, profound sedation, and the potential for dependence or abuse. Patients should be closely monitored for signs of respiratory compromise, especially after dose escalation or when combined with other central nervous system depressants.

Lacedor is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, those with severe respiratory insufficiency, acute or severe bronchial asthma, and individuals who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for the elderly and patients with compromised renal or hepatic function.